Resin Versus Glass Microspheres for Y-90 Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry

作者：Van Der Gucht Axel; Jreige Mario; Denys Alban^*; Blanc Durand Paul; Boubaker Ariane; Pomoni Anastasia; Mitsakis Periklis; Silva Monteiro Marina; Gnesin Silvano; Lalonde Marie Nicod; Duran Rafael; Prior John O; Schaefer Niklaus

来源：Journal of Nuclear Medicine, 2017, 58(8): 1334-1340.

DOI：10.2967/jnumed.116.184713

• Y-90
• TARE
• hepatocellular carcinoma
• survival
• partition model dosimetry

The aim of this study was to compare survival of patients treated for unresectable hepatocellular carcinoma (uHCC) with Y-90 transarterial radioembolization (TARE) using pretreatment partition model dosimetry (PMD). Methods: We performed a retrospective analysis of prospectively collected data on 77 patients consecutively treated (mean age +/- SD, 66.4 +/- 12.2 y) for uHCC (36 uninodular, 5 multinodular, 36 diffuse) with Y-90 TARE (41 resin, 36 glass) using pretreatment PMD. Study endpoints were progression-free survival (PFS) and overall survival (OS) assessed by Kaplan-Meier estimates. Several variables including Barcelona Clinic Liver Cancer (BCLC) staging system, tumor size, and serum a-fetoprotein (AFP) level were investigated using Cox proportional hazards regression. Results: The characteristics of 2 groups were comparable with regard to demographic data, comorbidities, Child-Pugh score, BCLC, serum AFP level, and Y-90 global administered activity. The median follow-up time was 7.7 mo (range, 0.4-50.1 mo). Relapse occurred in 44 patients (57%) at a median of 6 mo (range, 0.427.9 mo) after Y-90 TARE, and 41 patients (53%) died from tumor progression. Comparison between resin and glass microspheres revealed higher but not statistically significantly PFS and OS rates in the Y-90 resin group than the Y-90 glass group (resin PFS 6.1 mo [95% confidence interval CI, 4.7-7.4] and glass PFS 5 mo [95% CI, 0.9-9.2], P = 0.53; resin OS 7.7 mo [95% CI, 7.2-8.2] and glass OS 7 mo [95% CI 1.6-12.4], P = 0.77). No significant survival difference between both types of Y-90 microspheres was observed in any subgroups of patients with early/intermediate or advanced BCLC stages. Among the variables investigated, Cox analyses showed that only in the glass group, the BCLC staging system and the serum AFP level were associated with PFS (P = 0.04) and OS (P = 0.04). Tumor size was a prognostic factor without significant influence on PFS and OS after Y-90 TARE. Conclusion: Comparison between resin and glass microspheres revealed no significant survival difference in patients treated for uHCC with Y-90 TARE using pretreatment PMD. Further, larger prospective studies are warranted to confirm these findings.

• 出版日期2017-8-1